335 related articles for article (PubMed ID: 33584701)
1. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Bear AS; Vonderheide RH; O'Hara MH
Cancer Cell; 2020 Dec; 38(6):788-802. PubMed ID: 32946773
[TBL] [Abstract][Full Text] [Related]
3. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic ductal adenocarcinoma: a review of immunologic aspects.
Wachsmann MB; Pop LM; Vitetta ES
J Investig Med; 2012 Apr; 60(4):643-63. PubMed ID: 22406516
[TBL] [Abstract][Full Text] [Related]
5. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
Bazhin AV; Shevchenko I; Umansky V; Werner J; Karakhanova S
Cancer Immunol Immunother; 2014 Jan; 63(1):59-65. PubMed ID: 24129765
[TBL] [Abstract][Full Text] [Related]
6. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer.
Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
8. A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy.
Zhou Z; Van der Jeught K; Li Y; Sharma S; Yu T; Moulana I; Liu S; Wan J; Territo PR; Opyrchal M; Zhang X; Wan G; Lu X
Adv Sci (Weinh); 2023 Aug; 10(23):e2300548. PubMed ID: 37271874
[TBL] [Abstract][Full Text] [Related]
9. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.
Hilmi M; Delaye M; Muzzolini M; Nicolle R; Cros J; Hammel P; Cardot-Ruffino V; Neuzillet C
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1129-1142. PubMed ID: 37866368
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma.
Patterson MT; Burrack AL; Xu Y; Hickok GH; Schmiechen ZC; Becker S; Cruz-Hinojoza E; Schrank PR; Kennedy AE; Firulyova MM; Miller EA; Zaitsev K; Williams JW; Stromnes IM
Cell Rep; 2023 Jul; 42(7):112732. PubMed ID: 37402168
[TBL] [Abstract][Full Text] [Related]
11. Promising Therapeutic Approach in Pancreatic Cancer: Metabolism-Related Genes.
Choe S; Kwak W; Kim E; Shin S; Shin M; Koh HJ; Yoon H
Front Biosci (Landmark Ed); 2024 Apr; 29(4):137. PubMed ID: 38682209
[TBL] [Abstract][Full Text] [Related]
12. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma.
Kim IK; Diamond MS; Yuan S; Kemp SB; Kahn BM; Li Q; Lin JH; Li J; Norgard RJ; Thomas SK; Merolle M; Katsuda T; Tobias JW; Baslan T; Politi K; Vonderheide RH; Stanger BZ
Nat Commun; 2024 Feb; 15(1):1532. PubMed ID: 38378697
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
Kimbara S; Kondo S
World J Gastroenterol; 2016 Sep; 22(33):7440-52. PubMed ID: 27672267
[TBL] [Abstract][Full Text] [Related]
14. B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer.
Michaud D; Mirlekar B; Steward C; Bishop G; Pylayeva-Gupta Y
Front Immunol; 2021; 12():745873. PubMed ID: 35046933
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality.
Donahue TR; Dawson DW
Trends Endocrinol Metab; 2016 Nov; 27(11):770-781. PubMed ID: 27461042
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
McCormick KA; Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Hum Vaccin Immunother; 2016 Mar; 12(3):563-75. PubMed ID: 26619245
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer.
Du W; Pasca di Magliano M; Zhang Y
Front Oncol; 2021; 11():682217. PubMed ID: 34290984
[TBL] [Abstract][Full Text] [Related]
18. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer.
Curcio C; Brugiapaglia S; Bulfamante S; Follia L; Cappello P; Novelli F
Molecules; 2021 Mar; 26(6):. PubMed ID: 33804240
[TBL] [Abstract][Full Text] [Related]
19. Top advances of the year: Pancreatic cancer.
Warren EAK; Lesinski GB; Maithel SK
Cancer; 2023 Dec; 129(24):3843-3851. PubMed ID: 37776536
[TBL] [Abstract][Full Text] [Related]
20. Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line.
Schröter P; Hartmann L; Osen W; Baumann D; Offringa R; Eisel D; Debus J; Eichmüller SB; Rieken S
Sci Rep; 2020 Jan; 10(1):686. PubMed ID: 31959787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
